Literature DB >> 15921792

The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study.

Alex Zaphiriou1, Stephen Robb, Tarita Murray-Thomas, Gustavo Mendez, Kevin Fox, Theresa McDonagh, Suzanna M C Hardman, Henry J Dargie, Martin R Cowie.   

Abstract

OBJECTIVES: To determine the diagnostic accuracy of the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NTproBNP) in patients referred by their general practitioners (GPs) with symptoms suggestive of heart failure. Additionally, to compare the diagnostic accuracy of the resting 12-lead electrocardiogram (ECG) with that of the peptides.
DESIGN: A diagnostic accuracy study.
SETTING: Rapid-access heart failure clinics in five hospitals. PARTICIPANTS: 306 patients referred by their GPs with suspected heart failure. MAIN OUTCOME MEASURES: Sensitivity, specificity, positive and negative predictive values (PPV and NPV) and positive and negative likelihood ratios for BNP, NTproBNP and the ECG for the diagnosis of heart failure. Area under the receiver operating characteristics (ROC) curves for the two natriuretic peptides.
RESULTS: The diagnosis of heart failure was confirmed in 104 (34%) patients. The area under the ROC curve was 0.84 [95% CI 0.79-0.89] for BNP and 0.85 [0.81-0.90] for NTproBNP. At the manufacturers' recommended decision cut-points, NTproBNP provided a higher NPV (0.97) than BNP (0.87), but at lower PPV (0.44 versus 0.59). An abnormal ECG did not add any further predictive value to that of NTproBNP.
CONCLUSIONS: We have confirmed the value of the measurement of plasma BNP or NTproBNP as a 'rule-out' test for heart failure in patients currently referred by GPs to rapid access diagnostic clinics. A simple classification of the 12-lead ECG into 'normal' or 'abnormal' adds little value to ruling out heart failure in these circumstances. Further work is necessary to establish the best decision cut-points for use in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15921792     DOI: 10.1016/j.ejheart.2005.01.022

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  49 in total

1.  Acute heart failure: new diagnostic perspectives for the emergency physician.

Authors:  Gino Soldati; Luna Gargani; Fernando R Silva
Journal:  Intern Emerg Med       Date:  2008-02-09       Impact factor: 3.397

Review 2.  Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.

Authors:  Min-Seok Kim; Ju-Hee Lee; Eung Ju Kim; Dae-Gyun Park; Sung-Ji Park; Jin Joo Park; Mi-Seung Shin; Byung Su Yoo; Jong-Chan Youn; Sang Eun Lee; Sang Hyun Ihm; Se Yong Jang; Sang-Ho Jo; Jae Yeong Cho; Hyun-Jai Cho; Seonghoon Choi; Jin-Oh Choi; Seong Woo Han; Kyung Kuk Hwang; Eun Seok Jeon; Myeong-Chan Cho; Shung Chull Chae; Dong-Ju Choi
Journal:  Korean Circ J       Date:  2017-09-18       Impact factor: 3.243

3.  Point-of-care B-type natriuretic peptide and portable echocardiography for assessment of patients with suspected heart failure in primary care: rationale and design of the three-part Handheld-BNP program and results of the training study.

Authors:  Caroline Morbach; Thomas Buck; Christian Rost; Sebastian Peter; Stephan Günther; Stefan Störk; Christiane Prettin; Raimund Erbel; Georg Ertl; Christiane E Angermann
Journal:  Clin Res Cardiol       Date:  2017-11-15       Impact factor: 5.460

4.  Relationship of disease-associated gene expression to cardiac phenotype is buffered by genetic diversity and chromatin regulation.

Authors:  Elaheh Karbassi; Emma Monte; Douglas J Chapski; Rachel Lopez; Manuel Rosa Garrido; Joseph Kim; Nicholas Wisniewski; Christoph D Rau; Jessica J Wang; James N Weiss; Yibin Wang; Aldons J Lusis; Thomas M Vondriska
Journal:  Physiol Genomics       Date:  2016-06-10       Impact factor: 3.107

5.  On the search for the right definition of heart failure with preserved ejection fraction.

Authors:  Agnieszka Kapłon-Cieślicka; Karolina Kupczyńska; Piotr Dobrowolski; Błażej Michalski; Miłosz J Jaguszewski; Waldemar Banasiak; Paweł Burchardt; Łukasz Chrzanowski; Szymon Darocha; Justyna Domienik-Karłowicz; Jarosław Drożdż; Marcin Fijałkowski; Krzysztof J Filipiak; Marcin Gruchała; Ewa A Jankowska; Piotr Jankowski; Jarosław D Kasprzak; Wojciech Kosmala; Piotr Lipiec; Przemysław Mitkowski; Katarzyna Mizia-Stec; Piotr Szymański; Agnieszka Tycińska; Wojciech Wańha; Maciej Wybraniec; Adam Witkowski; Piotr Ponikowski; On Behalf Of "Club 30" Of The Polish Cardiac Society
Journal:  Cardiol J       Date:  2020-09-28       Impact factor: 2.737

6.  What the General Practitioner Needs to Know About Their Chronic Heart Failure Patient.

Authors:  Frans H Rutten; Joe Gallagher
Journal:  Card Fail Rev       Date:  2016-11

7.  Prospective evaluation and long-term follow-up of patients referred to secondary care based upon natriuretic peptide levels in primary care.

Authors:  John Gierula; Richard M Cubbon; Maria F Paton; Rowenna Byrom; Judith E Lowry; Sarah F Winsor; Melanie McGinlay; Emma Sunley; Emma Pickles; Lorraine C Kearney; Aaron Koshy; Thomas A Slater; Hemant K Chumun; Haqeel A Jamil; Kristian M Bailey; Julian H Barth; Mark T Kearney; Klaus K Witte
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2019-07-01

Review 8.  Biomarkers in heart failure: a clinical review.

Authors:  J Paul Rocchiccioli; John J V McMurray; Anna F Dominiczak
Journal:  Heart Fail Rev       Date:  2008-12-03       Impact factor: 4.214

9.  Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review.

Authors:  Ronald A Booth; Stephen A Hill; Andrew Don-Wauchope; P Lina Santaguida; Mark Oremus; Robert McKelvie; Cynthia Balion; Judy A Brown; Usman Ali; Amy Bustamam; Nazmul Sohel; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

Review 10.  Non-cardiac comorbidities in chronic heart failure.

Authors:  Chim C Lang; Donna M Mancini
Journal:  Heart       Date:  2006-02-17       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.